![Inhibition of FLT3-ITD signaling by AG1295 or PKC412 leads to induction... | Download Scientific Diagram Inhibition of FLT3-ITD signaling by AG1295 or PKC412 leads to induction... | Download Scientific Diagram](https://www.researchgate.net/profile/Andreas-Villunger/publication/23640109/figure/fig2/AS:601604319354882@1520445055108/Inhibition-of-FLT3-ITD-signaling-by-AG1295-or-PKC412-leads-to-induction-of-apoptosis.png)
Inhibition of FLT3-ITD signaling by AG1295 or PKC412 leads to induction... | Download Scientific Diagram
![PDF] Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. | Semantic Scholar PDF] Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/b825a5d927ce38433166e20b17c67b5fa1f2f0b6/6-Table6-1.png)
PDF] Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. | Semantic Scholar
![Dose–response curves of PKC412 for MOLM13, MOLM14, MV4-11, KOPB-26,... | Download Scientific Diagram Dose–response curves of PKC412 for MOLM13, MOLM14, MV4-11, KOPB-26,... | Download Scientific Diagram](https://www.researchgate.net/profile/Keita-Kirito/publication/6476697/figure/fig4/AS:268001236746292@1440907882997/Dose-response-curves-of-PKC412-for-MOLM13-MOLM14-MV4-11-KOPB-26-THP-1-BALL-1-KG-1.png)
Dose–response curves of PKC412 for MOLM13, MOLM14, MV4-11, KOPB-26,... | Download Scientific Diagram
![FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development - Kiyoi - 2020 - Cancer Science - Wiley Online Library FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development - Kiyoi - 2020 - Cancer Science - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/9ed74f16-824d-4c67-a978-2b4ad7fb8ed9/cas14274-fig-0003-m.jpg)
FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development - Kiyoi - 2020 - Cancer Science - Wiley Online Library
![Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia | Leukemia Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41375-020-01050-y/MediaObjects/41375_2020_1050_Fig1_HTML.png)
Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia | Leukemia
![Primary clinical resistance to PKC412 therapy in an AML patient with... | Download Scientific Diagram Primary clinical resistance to PKC412 therapy in an AML patient with... | Download Scientific Diagram](https://www.researchgate.net/profile/Lars-Roennstrand/publication/23789084/figure/fig1/AS:310132098519040@1450952662596/Primary-clinical-resistance-to-PKC412-therapy-in-an-AML-patient-with-FLT3-ITD627E-A.png)
Primary clinical resistance to PKC412 therapy in an AML patient with... | Download Scientific Diagram
![Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer - Annals of Oncology Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/374b7595-108f-4130-87b5-bd8379e7eb64/gr1.jpg)
Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer - Annals of Oncology
![Synergistic effect of all‑trans retinoic acid in combination with protein kinase C 412 in FMS-like tyrosine kinase 3-mutated acute myeloid leukemia cells Synergistic effect of all‑trans retinoic acid in combination with protein kinase C 412 in FMS-like tyrosine kinase 3-mutated acute myeloid leukemia cells](https://www.spandidos-publications.com/article_images/mmr/11/5/MMR-11-05-3969-g02.jpg)
Synergistic effect of all‑trans retinoic acid in combination with protein kinase C 412 in FMS-like tyrosine kinase 3-mutated acute myeloid leukemia cells
Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function | Haematologica
![The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations | Oncogene The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations | Oncogene](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsj.onc.1210980/MediaObjects/41388_2008_Article_BF1210980_Fig1_HTML.jpg)
The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations | Oncogene
![Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia | Bone Marrow Transplantation Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia | Bone Marrow Transplantation](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41409-020-01153-1/MediaObjects/41409_2020_1153_Fig1_HTML.png)
Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia | Bone Marrow Transplantation
![Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain - ScienceDirect Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497120678181-gr5.jpg)
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain - ScienceDirect
![Kinase inhibition by PKC412 prevents epithelial sheet damage in autosomal dominant epidermolysis bullosa simplex via keratin and cell contact stabilization - ScienceDirect Kinase inhibition by PKC412 prevents epithelial sheet damage in autosomal dominant epidermolysis bullosa simplex via keratin and cell contact stabilization - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0022202X22015317-fx1.jpg)
Kinase inhibition by PKC412 prevents epithelial sheet damage in autosomal dominant epidermolysis bullosa simplex via keratin and cell contact stabilization - ScienceDirect
![Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer - Annals of Oncology Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/53b5c06b-1056-4e2d-8547-b70e8b8bc226/gr2.jpg)